UB Paderborn / Katalog / Suche / in CDI

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.38-14, Article 38

2019

Link zum Volltext

Verfügbarkeit prüfen

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

Vaccines (Basel), 2022-03, Vol.10 (4), p.508

2022

Link zum Volltext

Verfügbarkeit prüfen

Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity

Vaccines (Basel), 2024-04, Vol.12 (4), p.388

2024

Link zum Volltext

Verfügbarkeit prüfen

Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells

International immunology, 2012-10, Vol.24 (10), p.625-636

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

Vaccine: X, 2022-08, Vol.11, p.100189-100189, Article 100189

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Cancer Immunology, Immunotherapy, 2019-05, Vol.68 (5), p.799-812

2019

Link zum Volltext

Verfügbarkeit prüfen

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

Vaccine, 2019-03, Vol.37 (13), p.1819-1826

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunosenescence and Cytomegalovirus: where do we stand after a decade?

Immunity & ageing, 2010-09, Vol.7 (1), p.13-13, Article 13

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

BMC cancer, 2014-10, Vol.14 (1), p.748-748, Article 748

2014

Link zum Volltext

Verfügbarkeit prüfen

A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines

Human vaccines & immunotherapeutics, 2013-10, Vol.9 (10), p.2263-2276

2013

Link zum Volltext

Verfügbarkeit prüfen

A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics

British journal of clinical pharmacology, 2020-06, Vol.86 (6), p.1139-1149

2020

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas

Cancer research (Chicago, Ill.), 2009-11, Vol.69 (21), p.8412-8419

2009

Link zum Volltext

Verfügbarkeit prüfen

Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses

Kidney international, 2010-11, Vol.78 (9), p.934-940

2010

Link zum Volltext

Verfügbarkeit prüfen

Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and function

Journal of virology, 2015-01, Vol.89 (1), p.568-580

2015

Link zum Volltext

Verfügbarkeit prüfen

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

Oncoimmunology, 2016-12, Vol.5 (12), p.e1249560-e1249560

2016

Link zum Volltext

Verfügbarkeit prüfen

Alloantigen-induced regulatory CD8+ CD103+ T cells

Human immunology, 2008-11, Vol.69 (11), p.737-744

2008

Link zum Volltext

Verfügbarkeit prüfen

A large multicenter, randomized, double-blind, crossover study in healthy volunteers, comparing pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar pegfilgrastim with European and United States reference pegfilgrastim

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23118-e23118

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2161-2161

2020

Link zum Volltext

Verfügbarkeit prüfen

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.79-79.7

2017

Link zum Volltext

Verfügbarkeit prüfen

Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans

Journal for immunotherapy of cancer, 2014-11, Vol.2 (Suppl 3), p.P172-P172, Article P172

2014

Link zum Volltext

Verfügbarkeit prüfen

Messenger RNA vaccination and B-cell responses in NSCLC patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2573-2573

2012

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part

Journal for immunotherapy of cancer, 2014-11, Vol.2 (Suppl 3), p.P85-P85

2014

Link zum Volltext

Verfügbarkeit prüfen

A novel, disruptive vaccination technology: Self-adjuvanted RNActive

Human vaccines & immunotherapeutics, 2013-06, Vol.9 (10), p.2263-2276

2013

Link zum Volltext

Verfügbarkeit prüfen

S100A1 Genetically Targeted Therapy Reverses Dysfunction of Human Failing Cardiomyocytes

Journal of the American College of Cardiology, 2011-08, Vol.58 (9), p.966-973

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity

Analysis of stem-cell-like properties of human CD161++IL-18Rα+ memory CD8+ T cells

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

Immunosenescence and Cytomegalovirus: where do we stand after a decade?

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines

A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas

Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses

Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and function

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

Alloantigen-induced regulatory CD8+ CD103+ T cells

A large multicenter, randomized, double-blind, crossover study in healthy volunteers, comparing pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar pegfilgrastim with European and United States reference pegfilgrastim

Abstract 2161: Identifying GDF-15 as potential novel immunotherapeutic target linked to immune cell exclusion in tumors and resistance to anti-PD-1 treatment

RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans

Messenger RNA vaccination and B-cell responses in NSCLC patients

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part

A novel, disruptive vaccination technology: Self-adjuvanted RNActive

S100A1 Genetically Targeted Therapy Reverses Dysfunction of Human Failing Cardiomyocytes

Suchergebnisse filtern